Agenus Inc. (AGEN)

Overview

Agenus Inc. is a clinical-stage biotechnology company focusing on the discovery and development of immuno-oncology products, with operations spanning the United States and international markets. Established in 1994 and initially known as Antigenics Inc., the company underwent a rebranding to Agenus Inc. in January 2011. Situated in Lexington, Massachusetts, Agenus leverages its expertise in immuno-oncology to develop a broad array of therapeutic agents and vaccines aimed at treating various cancers. The company operates under several trademarks, including Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon. It also boasts strategic collaborations with leading pharmaceutical and biotechnology companies like Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc.

Products and Services

Retrocyte Display: This advanced antibody expression platform specializes in the identification of fully human and humanized monoclonal antibodies. Its technology facilitates the discovery and development of therapeutic antibodies with high specificity and efficacy.

QS-21 Stimulon: A saponin-based vaccine adjuvant used to enhance the body’s immune response to vaccines. QS-21 Stimulon is part of the company's adjuvant portfolio aimed at improving the effectiveness of vaccines against infectious diseases and cancers.

Balstilimab: An anti-PD-1 antagonist currently in Phase II clinical trials for the treatment of second-line cervical cancer. This product represents Agenus' efforts to advance the treatment options available for cervical cancer patients.

AGEN1181: A CTLA-4 blocking antibody under Phase 2 clinical trial aiming to treat conditions such as pancreatic cancer and melanoma. AGEN1181 showcases the company’s commitment to developing treatments for hard-to-treat cancers.

AGEN2373: A CD137 monospecific antibody in Phase 1b clinical trial, representing the company's work in targeting specific cancer cell proteins to enhance the immune system's ability to fight cancer.

AGEN1423: This CD73/TGFß TRAP antibody is part of Agenus’ portfolio geared towards inhibiting cancer growth and proliferation.

AGEN1571: An ILT2 monospecific antibody in Phase 1 clinical trial, showcasing the company’s exploration of novel targets to stimulate an immune response against cancer cells.

BMS-986442: A TIGIT bispecific antibody developed in collaboration with Bristol-Myers Squibb, highlighting Agenus' expertise in bi-specific antibody development.

Other Products: The company is also developing INCAGN1876 (GITR agonist), INCAGN2390 (TIM-3 monospecific antibody), INCAGN2385 (LAG-3 monospecific antibody), MK-4830 (an ILT4 targeting monospecific antibody in Phase 2 trial), UGN-301 (a zalifrelimab intravesical solution for urinary tract cancers in Phase 1 trial), and AGEN1884 (a first-generation anti-CTLA-4 monospecific antibody). These products underscore Agenus’ diverse approach to fighting cancer through various pathways and mechanisms.